H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $98 citing "progress on multiple fronts." The analyst reiterates a Buy rating on the shares following the company's Q2 results. With Adcetris' "strong" launch in frontline classical Hodgkin's lymphoma and record high quarter-to-quarter sales growth in hand, Seattle Genetics is ready to deliver "yet another near-term catalyst" in early Q4 with the topline results of the ECHELON-2 trial, Fein tells investors in a research note. He believes Adcetris plus cyclophosphamide, doxorubicin, and prednisone could offer significant improvement over current combination chemotherapy regimen in treating frontline mature T-cell lymphoma patients.